CompanyGraph
What stands out
- Returns appear driven by leverage
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $9.23B, above the global median of $1.15B
- PositionOperating margin is 49%, higher than 95% of its Biotechnology peers (median -23.8%)
- Interpretations12 currently firing — 12
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
What stands out
- Returns appear driven by leverage
Financials view
Market Capitalization
9.23BUSDvs all stocks (USD)
Trailing P/E
27.21xvs Biotechnology peers
Revenue (TTM)
1.51BUSDvs all stocks (USD)
Profit Margin
23.13%vs Biotechnology peers
Beta
0.8370xvs all stocks
52-Week Change
39.15%vs all stocks
Market Capitalization
9.23BUSDvs all stocks (USD)
Enterprise Value
10.85BUSDvs all stocks (USD)
Trailing P/E
27.21xvs Biotechnology peers
Forward P/E
7.82xvs Biotechnology peers
PEG Ratio
0.8425xvs Biotechnology peers
Price to Sales (TTM)
6.10xvs Biotechnology peers
Price to Book (MRQ)
41.85xvs Biotechnology peers
Enterprise to Revenue
7.19xvs Biotechnology peers
Enterprise to EBITDA
11.39xvs Biotechnology peers
Gross Margin
78.97%vs Biotechnology peers
Profit Margin
23.13%vs Biotechnology peers
Operating Margin
48.98%vs Biotechnology peers
Return on Assets (TTM)
22.06%vs Biotechnology peers
Return on Equity (TTM)
99.40%vs Biotechnology peers
Revenue (TTM)
1.51BUSDvs all stocks (USD)
Revenue per Share (TTM)
12.72USDUpdated Jul 19, 2026Quarterly Revenue Growth
42.20%vs Biotechnology peers
Gross Profit (TTM)
1.16BUSDvs all stocks (USD)
EBITDA (TTM)
946.91MUSDvs all stocks (USD)
Net Income (TTM)
348.84MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
27.10%vs Biotechnology peers
Operating Cash Flow (TTM)
677.41MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
228.12MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
1.40BUSDFY2025 · Dec 31, 2025Cost of Goods Sold
228.77MUSDFY2025 · Dec 31, 2025Operating Income
802.59MUSDvs all stocks (USD)
Pre-tax Income
466.88MUSDFY2025 · Dec 31, 2025Income Tax Expense
149.99MUSDFY2025 · Dec 31, 2025Net Income
316.89MUSDFY2025 · Dec 31, 2025EBIT
485.00MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
890.64MUSDFY2025 · Dec 31, 2025Research & Development
81.49MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
207.09MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
18.13MUSDFY2025 · Dec 31, 2025EPS (Basic)
2.64USDFY2025 · Dec 31, 2025EPS (Diluted)
2.56USDFY2025 · Dec 31, 2025Basic Shares Outstanding
119.84MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
119.84MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
316.89MUSDFY2025 · Dec 31, 2025Operating Cash Flow
630.45MUSDFY2025 · Dec 31, 2025Free Cash Flow
623.48MUSDDerived from operating cash flow minus capital expenditure. This filing charges 88.05M of depreciation against 6.97M of capital expenditure, and its own free-cash-flow line reads 356.82M.FY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
136.42MUSDFY2025 · Dec 31, 2025Income Tax Paid
134.64MUSDFY2025 · Dec 31, 2025Interest Paid
11.43MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
316.89MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
88.05MUSDFY2025 · Dec 31, 2025Deferred Taxes (CF)
634.00KUSDFY2025 · Dec 31, 2025Stock-based Compensation
51.56MUSDFY2025 · Dec 31, 2025Other Non-cash Items
298.82MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-128.06MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
2.55MUSDFY2025 · Dec 31, 2025Capital Expenditures
-6.97MUSDFY2025 · Dec 31, 2025Net Intangibles (CF)
-287.77MUSDFY2025 · Dec 31, 2025Net Acquisitions
-725.97MUSDFY2025 · Dec 31, 2025Purchase of Investments
-247.35MUSDFY2025 · Dec 31, 2025Sale of Investments
722.25MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-258.04MUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
1.47BUSDFY2025 · Dec 31, 2025Long-term Debt Payments
-1.02BUSDFY2025 · Dec 31, 2025Common Stock Repurchase
-342.37MUSDFY2025 · Dec 31, 2025Other Financing Charges
-215.76MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
-107.00MUSDFY2025 · Dec 31, 2025Shares Outstanding
118.52MSharesUpdated Jul 19, 2026Float Shares
117.25MSharesUpdated Jul 19, 2026Shares Short
13.23MSharesUpdated Jul 19, 2026Short Ratio
6.94daysvs all stocks
Short % of Shares Outstanding
14.42%vs all stocks
% Held by Insiders
1.06%vs all stocks
% Held by Institutions
108.57%vs all stocks
Total Cash (MRQ)
318.62MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
2.69USDUpdated Jul 19, 2026Total Debt (MRQ)
2.18BUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
9.91xvs Biotechnology peers
Current Ratio (MRQ)
2.76xvs Biotechnology peers
Book Value per Share (MRQ)
1.85USDUpdated Jul 19, 2026Total Assets
2.53BUSDvs all stocks (USD)
Total Current Assets
825.21MUSDFY2025 · Dec 31, 2025Total Liabilities
2.48BUSDFY2025 · Dec 31, 2025Total Non-current Assets
1.70BUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
2.30BUSDFY2025 · Dec 31, 2025Total Current Liabilities
177.09MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
133.82MUSDFY2025 · Dec 31, 2025Other Short-term Investments
9.00MUSDFY2025 · Dec 31, 2025Accounts Receivable
434.27MUSDFY2025 · Dec 31, 2025Inventory
176.47MUSDFY2025 · Dec 31, 2025Accounts Payable
20.90MUSDFY2025 · Dec 31, 2025Long-term Debt
2.14BUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
113.86MUSDFY2025 · Dec 31, 2025Common Stock (Book)
118.00KUSDFY2025 · Dec 31, 2025Retained Earnings
54.79MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
48.81MUSDvs all stocks (USD)
52-Week Low
55.64USDUpdated Jul 19, 202652-Week High
82.26USDUpdated Jul 19, 202652-Week Change
39.15%vs all stocks
Beta
0.8370xvs all stocks
50-Day MA
71.12USDUpdated Jul 19, 2026200-Day MA
69.17USDUpdated Jul 19, 2026Avg 10-Day Volume
1.73MSharesUpdated Jul 19, 2026Avg 30-Day Volume
1.83MSharesUpdated Jul 19, 2026Diluted EPS (TTM)
2.85USDUpdated Jul 19, 2026Other Income / Expense
-317.59MUSDFY2025 · Dec 31, 202512 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Intangible Concentration
Much of what it owns is goodwill from past deals, large next to its equity.
Reads
How does this company use capital?
Diagnostic
Elevated ROE With High Debt-to-Equity and Equity Multiplier
Return on equity reads high on a balance sheet carrying a lot of debt against that equity.
Reads
Cash Backing With Revenue And Income Streaks
Revenue has risen in each of three years, profit in all three, and it holds more cash than debt.
Reads
Cash-Flow Ratios Elevated
More of its sales turn into cash than in its industry, and less of that cash is consumed by reinvestment than at most of its peers.
Reads
FCF Ratios Elevated
Its free cash flow is large next to assets and equity, and more of its operating cash reaches it than in its industry.
Reads
Industry-Benchmarked Return on Capital Elevated
It earns more on its assets and its equity than its industry, and gets more sales from those assets.
Reads
Operating Income Growing With Multi-Year Revenue Growth
Revenue up in each of five years, with operating income up in each of four.
Reads
Revenue Growing With Receivables Growing
Revenue has risen three years, and what customers owe has risen with it.
Reads
ROE, ROA, And Operating ROA Elevated
It earns more on its equity than its industry does, and on its assets too — not on borrowing alone.
Reads
Sales/Equity Elevated With Elevated Asset Turnover And Operating Margin
It gets more sales from its assets than its industry does, plenty from its equity too, and keeps a high operating margin.
Reads
Is this company growing?
Revenue Growth With Elevated Margin
Revenue up in each of five years, while its operating margin stays high.
Reads
Where is this company structurally exposed?
Receivables Heavy and Growing
Money owed by customers keeps growing, and is much of its current assets.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Operating margin is 49%, higher than 95% of its Biotechnology peers (median -23.8%)Significant
Operating margin: 0.49Industry median: -0.24Industry P95: 0.38Peers compared: 197
Return on equity is 99.4%, higher than 95% of its Biotechnology peers (median -24.5%)Significant
Return on equity: 0.99Industry median: -0.25Industry P95: 0.23Peers compared: 197
Return on assets is 22.1%, higher than 95% of its Biotechnology peers (median -21.3%)Significant
Return on assets: 0.22Industry median: -0.21Industry P95: 0.18Peers compared: 197
Debt-to-equity is 9.91×, higher than 95% of its Biotechnology peers (median 0.1×)Significant
Debt-to-equity: 9.91Industry median: 0.10Industry P95: 2.96Peers compared: 197
Price-to-book is 41.85×, higher than 95% of its Biotechnology peers (median 5.36×)Significant
Price-to-book: 41.85Industry median: 5.36Industry P95: 37.43Peers compared: 197
Structural Tensions
Returns appear driven by leverageSignificant
Return on Equity: 0.99Debt-to-Equity: 9.91
Financial Health
Altman Z-Score 3.76: safe zoneNotable
Altman Z-Score: 3.76
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $9.23B, above the global median of $1.15BNotable
Market cap (USD): 9,229,277,530Global Median: 1,146,734,693.424
Revenue is $1.51B, above the global median of $520.53MNotable
Revenue (USD): 1,508,457,984Global Median: 520,528,949.311
Levered free cash flow is $228.12M, above the global median of $16.24MNotable
Levered free cash flow (USD): 228,120,752Global Median: 16,239,329.704
Companies that share the same coordination system — how they create, deliver, or capture value.
Glaukos Corporation
Tier 1ProductionApproval-Gated PipelineRule
Aurobindo Pharma Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Protagonist Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Masimo Corporation
Tier 1ProductionApproval-Gated PipelineRuleFlow
Ionis Pharmaceuticals, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Kymera Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Crinetics Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Bruker Corporation
Tier 1ProductionApproval-Gated PipelineRuleFlow
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. A Shares
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Corcept Therapeutics Incorporated
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Groupe Dynamite Inc.
8 interpretationsSales/Equity Elevated With Elevated Asset Turnover And Operating MarginCash Backing With Revenue And Income StreaksFCF Ratios ElevatedROE, ROA, And Operating ROA ElevatedCash-Flow Ratios ElevatedElevated ROE With High Debt-to-Equity and Equity MultiplierOperating Income Growing With Multi-Year Revenue GrowthIndustry-Benchmarked Return on Capital Elevated
NVIDIA Corporation
8 interpretationsCash Backing With Revenue And Income StreaksFCF Ratios ElevatedROE, ROA, And Operating ROA ElevatedCash-Flow Ratios ElevatedRevenue Growing With Receivables GrowingOperating Income Growing With Multi-Year Revenue GrowthRevenue Growth With Elevated MarginIndustry-Benchmarked Return on Capital Elevated
Aena SME SA
6 interpretationsCash Backing With Revenue And Income StreaksFCF Ratios ElevatedROE, ROA, And Operating ROA ElevatedCash-Flow Ratios ElevatedOperating Income Growing With Multi-Year Revenue GrowthRevenue Growth With Elevated Margin